Company profile for Evommune

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Evommune is using the skin as the lens to uncover new approaches for accelerating the development of vital medicines across immunology and dermatology. Utilizing a novel screening platform, we identify molecules that are differentiated and that have a greater probability of being effective in treating patients. Our team has a track record of drug approvals and commercial successes. At Evommune, we are building off our extensiv...
Evommune is using the skin as the lens to uncover new approaches for accelerating the development of vital medicines across immunology and dermatology. Utilizing a novel screening platform, we identify molecules that are differentiated and that have a greater probability of being effective in treating patients. Our team has a track record of drug approvals and commercial successes. At Evommune, we are building off our extensive experience to connect disciplines that address inflammatory disease. Our dedication to science and innovation drives us in our pursuit to identify, discover, and develop unique and vital medicines.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Los Altos, California
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251211387121/en/Evommune-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update

BUSINESSWIRE
11 Dec 2025

https://www.prnewswire.com/news-releases/evommune-announces-closing-of-its-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares-302609041.html

PR NEWSWIRE
08 Nov 2025

https://www.prnewswire.com/news-releases/evommune-announces-pricing-of-its-initial-public-offering-302606409.html

PR NEWSWIRE BIO
05 Nov 2025

https://www.biospace.com/business/evommune-joins-ipo-class-with-planned-160m-raise-for-immuno-pipeline

BIOSPACE
31 Oct 2025

https://www.prnewswire.com/news-releases/evommune-announces-commencement-of-initial-public-offering-302599416.html

PR NEWSWIRE
30 Oct 2025

https://www.fiercebiotech.com/biotech/inflammation-biotech-evommune-eyes-ipo-fund-dermatitis-trials

FIERCE BIOTECH
10 Oct 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty